Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

FDA requests further data prior to phase II studies of APD-125 in chronic insomnia

March 31, 2006

Novartis and Servier sign licensing agreement for agomelatine

March 31, 2006

Lacosamide shows efficacy in treating epilepsy

March 31, 2006

SCA-136: a 5-HT2C agonist in phase II study for schizophrenia

March 31, 2006

Novel compounds with potential for the treatment of neurological disorders disclosed

March 30, 2006

New adenosine A2A antagonist from Schering-Plough in phase II for Parkinson's

March 30, 2006

Phase Ib study under way for neurodegenerative compound AL-208

March 30, 2006

New TRPV1 antagonists for pain profiled at ACS meeting

March 30, 2006

Pooled studies show efficacy of duloxetine in diabetic peripheral neuropathic pain

March 30, 2006

Continual paroxetine therapy reduces depression recurrence in the elderly

March 30, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...